Skip to content

The effect of plasma triglyceride-lowering therapy on the evolution of organ function in early predicted severe hypertriglyceridemia-induced acute pancreatitis (PERFORM study): rationale and design of a multicenter, prospective, observational study

The effect of plasma triglyceride-lowering therapy on the evolution of organ function in early predicted severe hypertriglyceridemia-induced acute pancreatitis (PERFORM study): rationale and design of a multicenter, prospective, observational study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000039541
Enrollment
Unknown
Registered
2020-10-30
Start date
2020-12-01
Completion date
Unknown
Last updated
2021-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe Acute Pancreatitis

Interventions

Medical therapy:Nil
Blood purification:Nil

Sponsors

Center of Severe Acute Pancreatitis,Department of Critical Care Medicine, Jinling Hospital, Medical School of Nanjing University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Aged between 18 to 70 years; 2. Within 72 hours of onset, With a primary diagnosis of HTG-AP; 3. When enrolled, TG>1000mg/dL (11.3mmol/L), accompanied by the clinical worrisome features of any one or more of the following: 1) Signs of hypocalcaemia (calcium levels less than 2.1mmol/L); 2) Lactic acidosis (Lactate levels more than 2mmol/L and PH 38.5 degrees C or 90 /min; Respiratory rate of >20 breaths/min or PaCO2 of 12,000 cells/mL, 10 percent immature (band) forms; 4) Signs of worsening organ dysfunction or multi-organ failure as defined by Modified Marshall scoring system for organ dysfunction.

Exclusion criteria

Exclusion criteria: 1. Without informed consent; 2. Pregnant or lactating women; or have a pregnancy plan within 1 month after the test (including male subjects); 3. Researchers family members who are directly involved in the trial; 4. Patients are expected to die within 48 hours after enrollment.

Design outcomes

Primary

MeasureTime frame
Organ failure free day;

Countries

China

Contacts

Public ContactZhihui Tong

Center of Severe Acute Pancreatitis, Department of Critical Care Medicine, Jinling Hospital, Medical School of Nanjing University

13270806915@163.com+86 13270806915

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 8, 2026